期刊文献+

Design, synthesis and biological evaluation of biphenylurea derivatives as VEGFR-2 kinase inhibitors(Ⅱ) 被引量:1

原文传递
导出
摘要 Inhibition of VEGFR-2 signaling pathway is one of the most promising approaches for the treatment of cancer. In this paper, we reported the design, synthesis, and biological evaluation of a series of biphenylurea derivatives as VEGFR-2 inhibitors. Among these compounds, 39 exhibited potent inhibitory activity against VEGFR-2 both in vitro and in vivo. The antiangiogenesis activity of 39 was further confirmed by both tube formation assay and chick chorioallantoic membrane assay. Inhibition of VEGFR-2 signaling pathway is one of the most promising approaches for the treatment of cancer. In this paper, we reported the design, synthesis, and biological evaluation of a series of biphenylurea derivatives as VEGFR-2 inhibitors. Among these compounds, 39 exhibited potent inhibitory activity against VEGFR-2 both in vitro and in vivo. The antiangiogenesis activity of 39 was further confirmed by both tube formation assay and chick chorioallantoic membrane assay.
出处 《Chinese Chemical Letters》 SCIE CAS CSCD 2016年第2期200-204,共5页 中国化学快报(英文版)
基金 the National Natural Science Foundation of China (Nos. 81273365, 81173080, 81321092) National Science & Technology Major Project ‘‘Key New Drug Creation and Manufacturing Program’’ (Nos. 2012ZX09103101-024, 2014ZX09304002-008-001) Chinese National Programs for High Technology Research and Development (No. 2012AA020302) the Shanghai Science and Technology Commission (No. 12DZ1930802) for their financial support
  • 相关文献

参考文献18

  • 1P. Carmeliet, Angiogenesis in health and disease, Nat. Med. 9 (2003) 653-660.
  • 2N. Ferrara, R.S. Kerbel, Angiogenesis as a therapeutic target, Nature 438 (2005) 96?-9?4.
  • 3Z.K. Otrock, J.A. Makarem, A.I. Shamseddine, Vascular endothelial growth factor family of ligands and receptors: review, Blood Cells. Mol. Dis. 38 (20071258-268.
  • 4A. Garofalo. A. Farce, S. Ravez, et al., Synthesis and structure-activity relationships of (Aryloxy) quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors, J. Med. Chem. 55 (20121 1189-1204.
  • 5K. Sanphanya, S.K. Wattanapitayakul, S. Phowichit, V.V. Fokin, O. Vajragupta, Novel VEGFR-2 kinase inhihitors identified by the back-to-front approach, Bioorg. Med. Chem. Lett. 23 (2013) 2962-296?.
  • 6H.M.W. Verheul, H.M. Pinedo, Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition, Nat. Rev. Cancer 7 (2007) 475-485.
  • 7R.A. Brekken, J.P. Overholser, V.A. Stastny, et al., Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/FIk-1) activity by a monoclonal anti-VECF antibody blocks tumor growth in mice, Cancer Res. 60 (2000) 5117- 5124.
  • 8X.W. Zhao, D. Liu, S.L. Luan, et al., Synthesis and biological evaluation of substi- tuted 1,2,3-benzotriazines and pyrido[M][3,2-d]-l,2,3-triazines as inhibitors of vascular endothelial growth factor receptor-2, Bioorg. Med. Chem. 21 (2013) 7807-7815.
  • 9T.A. Fong, L.K. Shawver, L. Sun, et al., SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (FIk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types, Cancer Res. 59 (1999) 99-106.
  • 10S. Wilhelm, C. Carter, M. Lynch, et al., Discovery and development of sorafenib: a multikinase inhibitor for treating cancer, Nat. Rev. Drug Discov. 5 (2006) 835-844.

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部